resectable and borderline resectable pancreatic cancer
Conditions
Interventions
gemcitabine (1000mg/m2) treated on day1,8,15,29,36,43,57,64,71 radiation thrapy
54gly(1.8Gly * 30days)
Sponsors
fukushima medical university
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) histopathologically diagnosed pancreatic cancer 2) performance status: 0-1 (eco grade) 3) pancreatic cancer, diagnosed as resectable by enhanced computed tomography 4) patient who expected to have more than 6 month survival at start of the treatment 5) patient with normal organ function white blood cell:>3500/mm3,<10,000/mm3 neutrophil: >2,000/mm3 lymphocyte: >1,500/mm3 platelet: >100,000/mm3 hemoglobin: >9.0g/dl total bilirubin: <2.0mg/dl ast, alt:>150 u/l serum creatinine:<1.2mg/dl
Exclusion criteria
Exclusion criteria: 1) unresectable pancreatic cancer 1 distant organ metastasis 2 peritoneal dissamination 3 para aortic lymph node metastasis 4 pancreatic cancer with artery invasion, such as abdominal aorta, superior mesenteric artery, ceriac artery, common hepatic artery, or proper hepatic artery. 5 portal vein invasion beyond reconstruction patient with interstitial lung disease or fibroid lung patient with severe diarrhea active viral infection excluding viral hepatitis patient with double cancer a woman of childbearing potential patient with severe psychological disorder patient with severe allergy to any drug
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| occurrence of side effect of preoperative gemcitabine based chemoradiation therapy | — |
Secondary
| Measure | Time frame |
|---|---|
| postoperative complication, 2-year recurrence-free survival, 2-year overall survival, recurrence site | — |
Countries
Japan
Contacts
Public ContactNaoya sato
Fukushima medical university Division of Hepato-Biliary-Pancreatic and Transplant surgery
Outcome results
None listed